Inadvertent post-expiry COVID-19 vaccination in 282 seniors: Safety, efficacy, and implications for extended off-label stability data.

IF 2.2 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Public Health in Practice Pub Date : 2026-05-10 eCollection Date: 2026-06-01 DOI:10.1016/j.puhip.2026.100802
Henrik Klasson
{"title":"Inadvertent post-expiry COVID-19 vaccination in 282 seniors: Safety, efficacy, and implications for extended off-label stability data.","authors":"Henrik Klasson","doi":"10.1016/j.puhip.2026.100802","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe safety and clinical outcomes after inadvertent post-expiry administration of Pfizer-BioNTech SARS-CoV-2 vaccine to adults aged ≥80 years in Swedish primary care; indicate what can (and cannot) be inferred about efficacy from real-world follow-up; and identify system needs for clearer expiry labelling and producer-led, longer-horizon post-expiry evidence. The study was not designed to estimate vaccine effectiveness.</p><p><strong>Study design: </strong>Service evaluation; observational single-arm cohort (ambispective).</p><p><strong>Methods: </strong>After discovery that 282 recipients had received doses 3-5 months past the labelled expiry, 280 survivors were informed and offered in-date revaccination within ∼4 weeks. Clinicians recorded revaccination uptake, adverse events exceeding expected post-mRNA symptoms after expired and (if applicable) in-date doses, and any confirmed/strongly suspected COVID-19 prior to revaccination; deaths were attributed via records. A change in manufacturer presentation of shortened/altered expiry encountered locally at point of care was documented.</p><p><strong>Results: </strong>208/280 accepted revaccination; 72/280 declined. Two deaths occurred from age-related/pre-existing illness (not vaccination-related). No serious or unexpected adverse events were recorded after expired or in-date doses. A small number reported mild, self-limited illness compatible with COVID-19; there were no hospitalisations and no laboratory-confirmed cases.</p><p><strong>Conclusions: </strong>In this cohort of older seniors, inadvertent post-expiry vaccination was followed by no safety signal and no COVID-19 hospitalisations; effectiveness cannot be quantified from this design. Given recurring human error and cold-chain stress, clearer expiry labelling and transparent, real-life post-expiry stability/efficacy data (weeks-months; including temperature-excursion profiles) are needed to support patient safety, reduce wastage, and strengthen preparedness.</p>","PeriodicalId":34141,"journal":{"name":"Public Health in Practice","volume":"11 ","pages":"100802"},"PeriodicalIF":2.2000,"publicationDate":"2026-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13196526/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.puhip.2026.100802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To describe safety and clinical outcomes after inadvertent post-expiry administration of Pfizer-BioNTech SARS-CoV-2 vaccine to adults aged ≥80 years in Swedish primary care; indicate what can (and cannot) be inferred about efficacy from real-world follow-up; and identify system needs for clearer expiry labelling and producer-led, longer-horizon post-expiry evidence. The study was not designed to estimate vaccine effectiveness.

Study design: Service evaluation; observational single-arm cohort (ambispective).

Methods: After discovery that 282 recipients had received doses 3-5 months past the labelled expiry, 280 survivors were informed and offered in-date revaccination within ∼4 weeks. Clinicians recorded revaccination uptake, adverse events exceeding expected post-mRNA symptoms after expired and (if applicable) in-date doses, and any confirmed/strongly suspected COVID-19 prior to revaccination; deaths were attributed via records. A change in manufacturer presentation of shortened/altered expiry encountered locally at point of care was documented.

Results: 208/280 accepted revaccination; 72/280 declined. Two deaths occurred from age-related/pre-existing illness (not vaccination-related). No serious or unexpected adverse events were recorded after expired or in-date doses. A small number reported mild, self-limited illness compatible with COVID-19; there were no hospitalisations and no laboratory-confirmed cases.

Conclusions: In this cohort of older seniors, inadvertent post-expiry vaccination was followed by no safety signal and no COVID-19 hospitalisations; effectiveness cannot be quantified from this design. Given recurring human error and cold-chain stress, clearer expiry labelling and transparent, real-life post-expiry stability/efficacy data (weeks-months; including temperature-excursion profiles) are needed to support patient safety, reduce wastage, and strengthen preparedness.

282例老年人意外到期后接种COVID-19疫苗:安全性、有效性和对扩展的超说明书稳定性数据的影响
目的:描述瑞典初级保健中年龄≥80岁的成年人意外使用辉瑞- biontech SARS-CoV-2疫苗过期后的安全性和临床结果;说明从现实世界的随访中可以(或不能)推断出哪些功效;并确定系统需要更清晰的过期标签和生产者主导的、更长期的过期后证据。这项研究的目的不是评估疫苗的有效性。研究设计:服务评价;观察性单臂队列(双视角)。方法:在发现282名受者接种了超过标签有效期3-5个月的疫苗后,280名幸存者被告知并在4周内及时重新接种疫苗。临床医生记录了重新接种疫苗的情况、过期和(如适用)有效剂量后超过预期的mrna后症状的不良事件,以及在重新接种疫苗之前任何确诊/强烈怀疑的COVID-19;死亡是通过记录确定的。记录了在当地医疗点遇到的缩短/更改有效期的制造商陈述的变化。结果:208/280接受再接种;72/280的拒绝。2例死亡发生于与年龄有关/已有疾病(与疫苗接种无关)。在过期或有效剂量后未记录严重或意外的不良事件。少数报告了与COVID-19相符的轻度自限性疾病;没有住院病例,也没有实验室确诊病例。结论:在该老年人队列中,未注意到过期后接种疫苗后没有安全信号,也没有COVID-19住院;这种设计无法量化有效性。鉴于反复出现的人为错误和冷链压力,需要更清晰的过期标签和透明的、真实的过期后稳定性/功效数据(周至月,包括温度变化情况),以支持患者安全、减少浪费和加强准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Public Health in Practice
Public Health in Practice Medicine-Health Policy
CiteScore
2.80
自引率
0.00%
发文量
117
审稿时长
71 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书